Episode 8: In the Clinic - Cervical cancer: Discussing the KEYNOTE A-18 trial with Dr Gemma Eminowicz

Send us Fan MailIn this episode we look at the KEYNOTE A-18 trial in cervical cancer with Dr Gemma Eminowicz. This trial was presented by Dr Domenica Lorusso at ESMO 2023 and published in The Lancet in March 2024.https://doi.org/10.1016/S0140-6736(24)00317-9This trial took a high-risk group of patients receiving chemoradiation for cervical cancer and they were randomised to placebo vs 2 years of pembrolizumab.The 2 year follow up results showed progression free survival benefit of 11%  in favour of 2 years of pembrolizumab (68% vs 57 %) with a Hazard Ratio of 0.7. Now we have 2 major trials (KEYNOTE A-18 and INTERLACE) in this chemoradiation space for cervical cancer we look at the similarities and differences between the trials.Where does this point to our new standard of care in cervical cancer?We hope you enjoyJohn & Mike(ENGOT-cx11/GOG-3047/KEYNOTE-A18)